Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis

Prasse, Antje; Zissel, Gernot; Lützen, Niklas; Schupp, Jonas C.; Schmiedlin, Rene; González‐Rey, Elena; Rensing‐Ehl, Anne; Bacher, Gerald; Cavalli, Vera Lúcia de Liz Oliveira; Bevec, Dorian; Delgado, Mario; Müller–Quernheim, Joachim

doi:10.1164/rccm.200909-1451oc

Cited by 146 publications

(121 citation statements)

References 34 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…An interesting study by PRASSE et al [27] reported on treatment of pulmonary sarcoidosis with inhaled vasoactive intestinal peptide. Treatment with vasoactive intestinal peptide was associated with significant changes in the release of several cytokines by alveolar macrophages retrieved by BAL.…”

Section: Other Agentsmentioning

confidence: 99%

Established and experimental medical therapy of pulmonary sarcoidosis

et al. 2013

View full text Add to dashboard Cite

The treatment options for pulmonary sarcoidosis have increased over the past 10 years. As new treatments have been introduced, the best way to assess and compare treatments remains unknown. The goal of this review is to discuss the standard treatments for pulmonary sarcoidosis, including glucocorticoids, and cytotoxic agents, such as methotrexate, azathioprine and leflunomide, and compare them to the newer biological agents, such as infliximab and adalimumab. We also discuss some novel treatments which are currently being evaluated. To compare these different regimens, we look at the measures used to assess response. These include pulmonary function, chest imaging, steroid sparing potential and, more recently, improvements in quality of life measures. While there is, as yet, no standard assessment for response, there is a growing consensus that response to treatment may include improvement of one or more of the following: forced vital capacity, chest imaging and steroid sparing. Several drugs used for pulmonary sarcoidosis have demonstrated improvement in one or more of these measures.

show abstract

Section: Other Agentsmentioning

confidence: 99%

Established and experimental medical therapy of pulmonary sarcoidosis

et al. 2013

View full text Add to dashboard Cite

show abstract

“…110 No adverse effects were reported after any of these trials. These results support the potential therapeutic role of inhaled vasoactive intestinal peptide agonists in treating asthma, pulmonary hypertension, and sarcoidosis.…”

Section: Vasoactive Intestinal Peptidementioning

confidence: 93%

Aerosolized Medications for Gene and Peptide Therapy

Laube

2015

Respir Care

View full text Add to dashboard Cite

Inhalation therapy has matured to include drugs that: (1) deliver nucleic acids that either lead to the restoration of a gene construct or protein coding sequence in a population of cells or suppress or disrupt production of an abnormal gene product (gene therapy); (2) deliver peptides that target lung diseases such as asthma, sarcoidosis, pulmonary hypertension, and cystic fibrosis; and (3) deliver peptides to treat diseases outside the lung whose target is the systemic circulation (systemic drug delivery). These newer applications for aerosol therapy are the focus of this paper, and I discuss the status of each and the challenges that remain to their successful development. Drugs that are highlighted include: small interfering ribonucleic acid to treat lung cancer and Mycobacterium tuberculosis; vectors carrying the normal alpha-1 antitrypsin gene to treat alpha-1 antitrypsin deficiency; vectors carrying the normal cystic fibrosis transmembrane conductance regulator gene to treat cystic fibrosis; vasoactive intestinal peptide to treat asthma, pulmonary hypertension, and sarcoidosis; glutathione to treat cystic fibrosis; granulocyte-macrophage colony-stimulating factor to treat pulmonary alveolar proteinosis; calcitonin for postmenopausal osteoporosis; and insulin to treat diabetes. The success of these new aerosol applications will depend on many factors, such as: (1) developing gene therapy formulations that are safe for acute and chronic administrations to the lung, (2) improving the delivery of the genetic material beyond the airway mucus barrier and cell membrane and transferring the material to the cell cytoplasm or the cell nucleus, (3) developing aerosol devices that efficiently deliver genetic material and peptides to their lung targets over a short period of time, (4) developing devices that increase aerosol delivery to the lungs of infants, (5) optimizing the bioavailability of systemically delivered peptides, and (6) developing peptide formulations for systemic delivery that do not cause persistent cough or changes in lung function.

show abstract

“…Based on these functions of the peptide, several clinical trials have been reported using VIP or its analog for asthma [45] and sarcoidosis [46]. Linden et al performed a double-blind, randomized, placebo controlled, crossover study for twenty four patients with moderate stable asthma [45].…”

Section: Clinical Trialsmentioning

confidence: 99%

“…They concluded that inhalation of a Ro25-1553 constituted a promising approach for bronchodilation in patients with asthma. Prasse A, et al reported their open clinical Phase II study where they treated twenty patients with histologically proved sarcoidosis with nebulized VIP for 4 weeks [46]. VIP inhalation significantly reduced production of tumor necrosis factoralpha by cells isolated from bronchoalveolar lavage CD4(+)CD127(-)CD25(+) T cells [46].…”

Section: Clinical Trialsmentioning

confidence: 99%

“…Prasse A, et al reported their open clinical Phase II study where they treated twenty patients with histologically proved sarcoidosis with nebulized VIP for 4 weeks [46]. VIP inhalation significantly reduced production of tumor necrosis factoralpha by cells isolated from bronchoalveolar lavage CD4(+)CD127(-)CD25(+) T cells [46]. They concluded that inhalation of VIP might be developed into a new therapeutic principle for chronic inflammatory lung of humans.…”

Section: Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation